** HK-listed shares of Laekna 2105.HK soar 37.2% to HK$14.54, highest since Jan. 11
** Stock set for biggest one-day pct rise since April 15
** Chinese biotech firm enters into agreement with Eli Lilly LLY.N to accelerate global clinical development of LAE102, used to treat obesity
** Under the deal, Lilly will fund and execute LAE102's phase I study in the U.S., while Laekna will retain the drug's global rights
** Hong Kong's healthcare index .HSCIH up 2.8%, while Hang Seng Index .HSI slips 0.1%
** Stock trims YTD losses to 32.3%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
